<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Non-Hodgkin Lymphoma

Research    Blood Cancer    Non-Hodgkin Lymphoma

Phase III clinical trial results support rituximab as new standard-of-care in pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. The trial represents a major international collaboration between the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the Children’s Oncology Group (COG), and was led in the United States by Thomas Gross, MD, PhD, University of Colorado Cancer Center investigator and pediatric oncologist at Children’s Hospital Colorado, and in Europe by Véronique Minard-Colin, MD and Catherine Patte, MD, both pediatric oncologists at the Gustave Roussy Department of Child and Adolescent Oncology in Paris, France. The addition of rituximab decreased treatment failures by 70 percent resulting in a 10 percent increase in the three-year survival rate seen with chemotherapy alone (LMB protocol).


Author Cancer Center | Publish Date June 03, 2020
Full Story

CU Cancer Center In the News

5280

No, Sun Exposure Is Not the Secret to Living Longer (Probably)

news outlet5280
Publish DateJanuary 05, 2022

CU Cancer Center member Neil Box, MD, separates fact from pseudoscience when it comes to protecting yourself from the sun.

Full Story
Denver 7

'I'm Just so Proud of Him': Crested Butte Family Shares 2-year-old's Journey with Kidney Cancer

news outletDenver 7
Publish DateDecember 23, 2021

In 2021, a Crested Butte family received a life-changing diagnosis. During the holiday season, their story is an apparent reminder that sometimes the best gifts are never found under a tree.

Full Story
Cure Today

Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients with Breast Cancer

news outletCure Today
Publish DateDecember 15, 2021

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

Full Story
Healio

Liso-cel Significantly Improves Outcomes in Second-Line DLBCL

news outletHealio
Publish DateDecember 11, 2021

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Full Story